AMENDMENTS TO THE CLAIMS

1 (currently amended). A pharmaceutical composition for oral administration comprising an active substance having a food effect, in combination with a reduced food effect effective amount of a lipid material comprising membrane lipids~~, characterised in showing a reduced food effec~~t.

2 (original). The pharmaceutical composition according to claim 1, wherein the content of membrane lipids is not less than 3% by weight of the lipid material.

3 (currently amended). The pharmaceutical composition according to claim 1 ~~or 2~~, wherein the membrane lipids contain digalactosyl- diacylglycerol in an amount not less than about 0.5 % by weight of the lipid material.

4 (currently amended). The pharmaceutical composition according to ~~any of claims 1-3~~ claim 1, wherein the lipid material comprises a fractionated cereal oil~~, preferably from oats~~.

5 (currently amended). The pharmaceutical composition according to ~~any of claims 1-4~~ claim 1, wherein the lipid material comprises non-polar lipids.

6 (currently amended). The pharmaceutical composition ~~according to any of the preceding claims~~ claim 1, wherein the composition comprises the active substance dissolved or dispersed in solid lipid particles with a diameter of not more than 20pm.

7 (currently amended). A pharmaceutical composition for oral administration according to claim 1 comprising from 0.5 to 12% by weight of the composition~~,~~

~~preferably 1 to 8 %,~~ of isotretinoin, and a lipid material comprising from 2% to 60% by weight of membrane lipids, and from 30 to 98% by weight of non-polar lipids, calculated on the lipid material.

8 (currently amended). A pharmaceutical composition for oral administration according to claim 1, comprising from 0.1 to 20 % by weight of an immunosuppressant, from 1 % to 40 % by weight of membrane lipids, and from 5 to 40 % by weight of monoglycerides, calculated on the composition.

9 (currently amended). A pharmaceutical composition for oral administration according to claim 1, comprising up to about 50 % by weight of an antiviral, from about 10 % to about 70% by weight of membrane lipids, and from about 10 % to about 70 % by weight of monoglycerides, calculated on the composition.

10 (currently amended). The pharmaceutical composition according to ~~any of the preceding claims~~ claim 1, wherein the lipid material comprises about 3 % to about 60% by weight of monoglycerides.

11 (currently amended). The pharmaceutical composition according to ~~any of claims 8-~~ claim 1, wherein the monoglycerides comprise medium chain monoglycerides.

12 (currently amended). The pharmaceutical composition according to ~~any of the preceding claims~~ claim 1, wherein the lipid material comprises at least 10% by weight of di-and triglycerides or a mixture thereof.

13 (currently amended). The pharmaceutical composition according to ~~any of the preceding claims~~ claim 1 comprising in addition a polar solvent.

14 (original). A pharmaceutical composition comprising solid lipid particles with a diameter of not more than about 20 um, comprising a) an active substance, dissolved or dispersed in said lipid particles, and b) a lipid material comprising membrane lipids.

15 (currently amended). The pharmaceutical composition according to ~~any of the preceding claims, showing a~~ claim 1, wherein the reduced food effect effective amount is sufficient to provide a reduction of at least 25%.

16 (currently amended). The pharmaceutical composition according to ~~any of the preceding claims~~, having a claim 1, wherein the food effect is less than 20%.

17 (cancelled).

18 (new) The pharmaceutical composition according to claim 2, wherein the lipid material comprises at least about 20 % by weight of fractionated oats oil.

19 (new) The pharmaceutical composition according to claim 1 ~~or 2~~, wherein the membrane lipids contain digalactosyl- diacylglycerol in an amount not less than about 0.5 % by weight of the lipid material, and the lipid material comprises non-polar lipids.

20 (new). The pharmaceutical composition claim 19, wherein the active substance is dissolved or dispersed in solid lipid particles with a diameter of not more than 20pm.

21 (new). The pharmaceutical composition according to claim 20, wherein the lipid material comprises about 3 % to about 60% by weight of monoglycerides, and at least 10% by weight of di-and triglycerides or a mixture thereof.